Trial Profile
A phase II study of axitinib for biliary tract cancer refractory to gemcitabine-based chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2013
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Adenosquamous carcinoma; Biliary cancer
- Focus Biomarker; Therapeutic Use
- Acronyms AX-BC
- 19 Apr 2013 New trial record